- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07277413
Eine Studie zu IDE892 als Monotherapie und in Kombination bei MTAP-deletierten fortgeschrittenen soliden Tumoren
Eine multizentrische Studie zur Bewertung der Sicherheit, Wirksamkeit und Pharmakokinetik von IDE892 als Monotherapie und Kombinationstherapie bei Teilnehmern mit MTAP-deletierten fortgeschrittenen soliden Tumoren
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.
Studienübersicht
Status
Bedingungen
- Bauchspeicheldrüsenkrebs
- Adenokarzinom des Magens
- Mesotheliom
- Blasenkrebs
- Peritoneales Mesotheliom
- Adenokarzinom der Speiseröhre
- Gallengangskarzinom
- Pleuramesotheliom
- Nicht-kleinzelliger Lungenkrebs NSCLC
- Gastroösophagealer Krebs (GC)
- NSCLC-Adenokarzinom
- Plattenepithelkarzinom. - Speiseröhre
- Urothelkarzinom (UC)
Intervention / Behandlung
Detaillierte Beschreibung
The purpose of this study is to evaluate safety, efficacy, and PK of IDE892 as monotherapy and combination therapy in adult participants with MTAP-deleted tumors who have progressed after standard therapy and represent a high unmet need. In the current stage, the combination will be focused on IDE892 with IDE397, an oral inhibitor of methionine adenosyltransferase 2A (MAT2A), to fully exploit the vulnerabilities associated with methylthioadenosine (MTA) accumulation in MTAP-deleted tumors while maintaining a substantial therapeutic index. The mechanistic rationale for this study is discussed in the following sections.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
- Name: IDEAYA Clinical Trials
- Telefonnummer: +1 855 433 2246
- E-Mail: IDEAYAClinicalTrials@ideayabio.com
Studienorte
-
-
Arizona
-
Goodyear, Arizona, Vereinigte Staaten, 85338
- Rekrutierung
- City of Hope Cancer Center-Phoenix
-
Kontakt:
- Amit Kulkarni, MD
- Telefonnummer: 612-624-9604
- E-Mail: amkulkarni@coh.org
-
Phoenix, Arizona, Vereinigte Staaten, 85054
- Rekrutierung
- Mayo Clinic Arizona
-
Kontakt:
- Mitesh J. Borad, M.D.
- Telefonnummer: 855-776-0015
-
-
California
-
Duarte, California, Vereinigte Staaten, 91010
- Rekrutierung
- City of Hope Cancer Center-Duarte
-
Kontakt:
- Abhishek Tripathi, M.D.
- Telefonnummer: 626-218-9200
- E-Mail: atripathi@coh.org
-
Santa Rosa, California, Vereinigte Staaten, 95403
- Rekrutierung
- Providence Medical Foundation
-
Kontakt:
- Ian Anderson, MD
- Telefonnummer: 707-521-3830
- E-Mail: ian.anderson@providence.org
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20016
- Rekrutierung
- Johns Hopkins Sibley Memorial Hospital
-
Kontakt:
- Solmaz Sahebjam, MD
- Telefonnummer: 202-669-6500
- E-Mail: ssahebj1@jh.edu
-
Kontakt:
- Mahlet Atnafu
- Telefonnummer: 202-669-6500
- E-Mail: SibleyOncResReferral@live.johnshopkins.edu
-
-
Florida
-
Coral Springs, Florida, Vereinigte Staaten, 33065
- Rekrutierung
- BRCR Global-Coral Springs
-
Kontakt:
- Alina Quintana
- Telefonnummer: 561-447-0614
- E-Mail: alinaq@brcrglobal.com
-
Jacksonville, Florida, Vereinigte Staaten, 32224
- Rekrutierung
- Mayo Clinic Florida
-
Kontakt:
- Conor D. O'Donnell, M.B., B.Ch., B.A.O.
- Telefonnummer: 855-776-0015
-
Orlando, Florida, Vereinigte Staaten, 32827
- Rekrutierung
- Sarah Cannon Research Institute at Florida Cancer Specialists
-
Kontakt:
- Elizabeth Gilmore
- Telefonnummer: 904-380-2410
- E-Mail: Elizabeth.Griffith@Scri.com
-
Tampa, Florida, Vereinigte Staaten, 33612
- Rekrutierung
- Moffitt Cancer Center
-
Kontakt:
- Mauricio Ribeiro, MD
- Telefonnummer: 813-745-3242
- E-Mail: mauricio.ribeiro@moffitt.org
-
Kontakt:
- Anisa Gonzalez
- Telefonnummer: 813-745-3874
- E-Mail: anisa.gonzalez@moffitt.org
-
-
Illinois
-
Zion, Illinois, Vereinigte Staaten, 60099
- Rekrutierung
- City of Hope Cancer Center-Chicago
-
Kontakt:
- Evan Pisick, M.D.
- Telefonnummer: 415-353-9674
- E-Mail: episick@coh.org
-
-
Minnesota
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Rekrutierung
- Mayo Clinic Rochester
-
Kontakt:
- Kaushal Parikh, M.B.B.S.
- Telefonnummer: 855-776-0015
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68130
- Rekrutierung
- Nebraska Cancer Specialists
-
Kontakt:
- Lindsey Becker, Primary Study Coordinator
- Telefonnummer: 402-691-5255
- E-Mail: lbecker@nebraskacancer.com
-
-
New Jersey
-
East Brunswick, New Jersey, Vereinigte Staaten, 08816
- Rekrutierung
- START Astera, LLC
-
Kontakt:
- Hope Team Distribution List
- E-Mail: hopeteam@startresearch.com
-
-
New York
-
New York, New York, Vereinigte Staaten, 10032
- Rekrutierung
- Columbia University Irving Medical Center
-
Kontakt:
- Nurse Navigation Team: Contact for All Patient Referrals
- Telefonnummer: 212-342-5162
- E-Mail: cancerclinicaltrials@cumc.columbia.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
- Rekrutierung
- Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University
-
Kontakt:
- E-Mail: askphase1@jefferson.edu
-
Kontakt:
- askphase1@jefferson.edu
- Telefonnummer: 215-586-0199
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- Rekrutierung
- Sarah Cannon Research Institute
-
Kontakt:
- Alydia Miller
- Telefonnummer: 615-927-2212
- E-Mail: alydia.miller@scri.com
-
Kontakt:
- Sarah Cannon Institute
- Telefonnummer: 844-482-4812
- E-Mail: asksarah@sarahcannon.com
-
-
Texas
-
Fort Worth, Texas, Vereinigte Staaten, 76104
- Rekrutierung
- START Dallas Fort Worth
-
Kontakt:
- Kasie Newton
- Telefonnummer: 682-350-3010
- E-Mail: kasie.newton@startresearch.com
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- MD Anderson
-
Kontakt:
- Jordi Rodon Ahnert, MD, PhD
- Telefonnummer: 713-563-1930
- E-Mail: JRodon@mdanderson.org
-
Houston, Texas, Vereinigte Staaten, 77054
- Rekrutierung
- NEXT Oncology Houston
-
Kontakt:
- Emma Morales
- Telefonnummer: 832-384-7912
- E-Mail: emorales@nextoncology.com
-
Irving, Texas, Vereinigte Staaten, 75039
- Rekrutierung
- NEXT Oncology Dallas
-
Kontakt:
- Mofopefoluwa Akinwale
- Telefonnummer: 972-893-8800
- E-Mail: fakinwale@nextoncology.com
-
-
Utah
-
West Valley City, Utah, Vereinigte Staaten, 84119
- Rekrutierung
- START Mountain Region, LLC
-
Kontakt:
- Marie Asay, Director, Nursing
- Telefonnummer: 801-907-4770
- E-Mail: marie.asay@startresearch.com
-
-
Virginia
-
Fairfax, Virginia, Vereinigte Staaten, 22031
- Rekrutierung
- NEXT Oncology Virginia
-
Kontakt:
- Maybelle De La Rosa
- Telefonnummer: 703-783-4518
- E-Mail: mdelarosa@nextoncology.com
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98104
- Rekrutierung
- Swedish Cancer Institute
-
Kontakt:
- Siddhartha Devarakonda, MD
- Telefonnummer: 206-386-2424
- E-Mail: siddhartha.devarakonda@swedish.org
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Are ≥ 18 years of age (or the minimum age of consent in accordance with local regulations) at the time of signing the ICF.
- Have a histologically confirmed diagnosis of a locally advanced recurrent or metastatic solid tumor type of interest with MTAP deletion (for dose escalation: mesothelioma [pleural or peritoneal], gastroesophageal cancers [squamous and adenocarcinoma of esophagus, gastric adenocarcinoma, gastroesophageal junction cancers], pancreatic adenocarcinoma and biliary tract carcinomas (intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder cancer), NSCLC [adenocarcinoma, squamous cell carcinoma, and adeno-squamous] or UC [including mixed urothelial-squamous histology]; for dose expansion: NSCLC that has progressed on at least one prior line of treatment and for which additional effective standard therapy is not available or for which the participant is not a candidate due to intolerance).
- Are willing and able to provide blood/tumor tissue samples for biomarker testing. An archival tumor tissue specimen must be provided for central confirmation of MTAP loss.
- Must be willing and able to provide the blood/serum/plasma samples
- Have evidence of homozygous loss of MTAP or MTAP deletion (pre-screening available after signing pre-screening ICF)
- Have at least 1 measurable lesion according to RECIST version 1.1
- Have Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1
- Have life expectancy > 3 months
- Have adequate bone marrow and organ function
- Able to swallow and retain orally administered study drug/IMP.
- Are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures
- Male and female: willing to use contraception
Exclusion Criteria:
- Known symptomatic brain metastases requiring supraphysiologic doses of systemic corticosteroids
- Have a known primary central nervous system (CNS) malignancy
- Have had other malignancies within 2 years prior to the first dose, with some exceptions
- Impaired cardiac function or clinically significant cardiac diseases
- Have presence of uncontrolled pleural, peritoneal, or pericardial effusion within 2 weeks before the first study dose, requiring recurrent drainage procedures or an indwelling drainage catheter
- Have a history of severe infections within 4 weeks prior to the start of study treatment
- Hypertension (e.g., > 150/100 mmHg) that cannot be controlled by medications despite optimal medical therapy
- Other acute or chronic medical or psychiatric condition
- Have a history of immunodeficiency, with a positive human immunodeficiency virus(HIV) test at screening
- Known or suspected viral hepatitis with a positive test at screening
- Had an adverse reaction to a previous antitumor treatment that has not recovered to CTCAE Grade ≤ 1
- Have received chemotherapy within 4 weeks of the first dose of IMP; immunotherapy or biologic targeted antitumor treatments within 2 weeks before the first dose of IMP; small molecule inhibitors within 2 weeks before the first dose of IMP, or other investigational products within 4 weeks
- Current radiation-related toxicity or radiation therapy within 2 weeks before the first dose of IMP
- Administration of any of the following within 2 weeks before the first dose of IDE892 as a monotherapy: Strong inhibitors or inducers of cytochrome P450, Strong inhibitors of P-glycoprotein, Narrow therapeutic index and sensitive substrates of multidrug and toxin extrusion (MATE)1 and MATE2-K, Narrow therapeutic index and sensitive substrates of P-gp and breast cancer resistance protein
- Administration of any of the following within 2 weeks before the first dose of IDE892: Strong inhibitors or inducers of CYP3A4/5, Strong inhibitors of P-gp and/or BCRP, Narrow therapeutic index and sensitive substrates of MATE1 and MATE2-K, Narrow therapeutic index and sensitive substrates of P-gp and BCRP
- Use of proton pump inhibitors (PPIs) within 7 days prior to the first dose of IMP or planned use during the study
- Use of drugs with known risk for QT prolongation within 2 weeks prior to the first dose of IDE892
- Previous treatment with a Amethionine adenosyltransferase 2A (MAT2A) inhibitor and/or Protein arginine N-methyltransferase (PRMT) inhibitor
- Major surgery within 4 weeks before study entry
- Prior irradiation to > 25% of the bone marrow
- Known or suspected hypersensitivity to IDE892
Disease-Specific Eligibility Criteria Eligibility Criteria for Participants with NSCLC (All Parts)
- Must have histologically confirmed diagnosis of advanced or metastatic NSCLC that has progressed after prior treatment with platinum chemotherapy and a PD-1/PD-L1 inhibitor (unless contraindicated or participant developed intolerance) in the metastatic setting
- Treatment with no more than 3 prior lines in the setting of advanced or metastatic disease.
- If considered standard of care and available, participants whose cancers have proven targetable oncogene alterations must have had disease progression on (unless contraindicated or participant developed intolerance) at least 1 prior line containing appropriate targeted therapy.
Eligibility Criteria for Participants with Urothelial Cancer (Bladder and Upper Urinary Tract), Mesothelioma (Pleural or Peritoneal), Pancreatic Adenocarcinoma or Biliary Tract Carcinomas (Intrahepatic and Extrahepatic Cholangiocarcinoma, and Gallbladder Cancer) (Parts 1 and 3)
- Must have histologically confirmed diagnosis of advanced or metastatic UC, mesothelioma, gastroesophageal cancer or pancreatic and biliary tract tumors
- Must have progressed following at least 1 prior line of therapy
- Treatment with no more than 3 prior lines in the setting of advanced or metastatic disease
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Part 1: IDE892 Monotherapy Dose Escalation (MTAP-deleted advanced solid tumors)
Participants with advanced or metastatic solid tumors harboring MTAP deletion (including mesothelioma, gastroesophageal cancers, pancreatic and biliary tract tumors, non-small cell lung cancer, and urothelial cancer) will receive IDE892. Dose levels will be escalated sequentially using a Bayesian Optimal Interval (BOIN) design to evaluate safety, tolerability, and to determine the maximum tolerated dose and/or recommended dose for expansion. PK and pharmacodynamics (PD) and preliminary antitumor activity will also be assessed. |
IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5) that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. |
|
Experimental: Part 2: IDE892 Monotherapy Dose Expansion (MTAP-Deleted NSCLC)
Participants with advanced or metastatic NSCLC with MTAP deletion will receive IDE892. One or more dose levels at or below the maximum tolerated dose from Part 1 will be further evaluated to determine the recommended Phase 2 dose and to assess antitumor activity. |
IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5) that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. |
|
Experimental: Part 3: IDE892 + IDE397 Combination Dose Escalation (MTAP-Deleted Solid Tumors)
Participants with advanced or metastatic solid tumors harboring MTAP deletion (including mesothelioma, gastroesophageal cancers, pancreatic and biliary tract tumors, non-small cell lung cancer, and urothelial cancer) will receive IDE892 in combination with IDE397. Dose levels will be escalated using a modified toxicity probability interval (mTPI) design to evaluate safety, tolerability, and to determine the maximum tolerated dose and/or recommended dose for expansion. PK, PD, and preliminary antitumor activity will also be assessed. |
IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5) that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. IDE397 is an oral MAT2A inhibitor that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. In this study, IDE397 will be evaluated in combination with IDE892 (Parts 3 and 4) in participants with MTAP-deleted advanced solid tumors. |
|
Experimental: Part 4: IDE892 + IDE397 Combination Dose Expansion (MTAP-Deleted NSCLC)
Participants with advanced or metastatic NSCLC with MTAP deletion will receive IDE892 in combination with IDE397. One or more dose levels at or below the maximum tolerated dose from Part 3 will be further evaluated to determine the recommended Phase 2 dose and to assess antitumor activity. |
IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5) that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. IDE397 is an oral MAT2A inhibitor that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. In this study, IDE397 will be evaluated in combination with IDE892 (Parts 3 and 4) in participants with MTAP-deleted advanced solid tumors. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of Dose-limiting Toxicities (DLTs) of IDE892 (Parts 1 and 3)
Zeitfenster: 21 days following the first dose of IDE892 (each cycle is 21 days)
|
Incidence of DLTs of IDE892 will be determined in Parts 1 and 3 |
21 days following the first dose of IDE892 (each cycle is 21 days)
|
|
Incidence of AEs and SAEs (Parts 1, 2, 3, and 4)
Zeitfenster: From first dose until 28 days after last dose (each cycle is 21 days)
|
Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) (graded based on Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) will be determined in Parts 1, 2, 3, and 4. |
From first dose until 28 days after last dose (each cycle is 21 days)
|
|
Objective response rate (ORR) and duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (Parts 2 and 4)
Zeitfenster: Approximately 2 years
|
Objective response rate (ORR: best objective response of complete response [CR] + partial response [PR]) and duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as assessed by the Investigator |
Approximately 2 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overall response rate (ORR) and duration of response (DOR) per RECIST version 1.1 (Parts 1 and 3)
Zeitfenster: Approximately 2 years
|
ORR and DOR per RECIST version 1.1 as assessed by the Investigator |
Approximately 2 years
|
|
Disease control rate (DCR) and duration of stable disease per RECIST version 1.1 (Parts 1, 2, 3, and 4)
Zeitfenster: Approximately 2 years
|
Disease control rate (disease control rate [DCR]: CR + PR + stable disease [SD]) and duration of SD per RECIST version 1.1 as assessed by the Investigator |
Approximately 2 years
|
|
Maximum Observed Plasma Concentration (Cmax) (Parts 1, 2, 3, and 4)
Zeitfenster: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Cmax is the highest observed plasma concentration of the study drug following administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Time to Maximum Observed Concentration (Tmax)
Zeitfenster: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Time to Maximum Observed Concentration (Tmax) after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Zeitfenster: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
AUClast reflects total drug exposure from dosing until the last measurable concentration after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Time of Last Quantifiable Concentration (Tlast)
Zeitfenster: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Tlast is the time at which the final measurable drug concentration is observed after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf)
Zeitfenster: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
AUCinf represents total drug exposure extrapolated to infinite time after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Terminal Elimination Half-Life (t½)
Zeitfenster: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
t½ is the time required for the plasma concentration of the drug to decrease by half during the terminal elimination phase after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Maximum Observed Plasma Concentration at Steady State (Cmax,ss)
Zeitfenster: Cycle 1 Day 15 (each cycle is 21 days)
|
Cmax,ss is the maximum observed plasma concentration after achieving steady state after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 15 (each cycle is 21 days)
|
|
Time to Maximum Concentration at Steady State (Tmax,ss)
Zeitfenster: Cycle 1 Day 15 (each cycle is 21 days)
|
Tmax,ss is the time from dosing to Cmax at steady state after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 15 (each cycle is 21 days)
|
|
Trough Plasma Concentration at Steady State (Ctrough)
Zeitfenster: Cycle 1 Day 15 (each cycle is 21 days)
|
Ctrough is the concentration obtained immediately prior to the next scheduled dose at steady state after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 15 (each cycle is 21 days)
|
|
Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUCtau)
Zeitfenster: Cycle 1 Day 15 (each cycle is 21 days)
|
AUCtau represents drug exposure over one full dosing interval at steady state after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 15 (each cycle is 21 days)
|
|
Apparent Clearance (CL/F)
Zeitfenster: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
CL/F is the apparent clearance of the drug after extravascular dosing after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Apparent Volume of Distribution (Vz/F)
Zeitfenster: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Vz/F is the apparent volume of distribution following extravascular dosing after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Accumulation Ratio (Rac)
Zeitfenster: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Rac is calculated as the ratio of AUC or Cmax at steady state compared with first dose, reflecting drug accumulation after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Edward Chan, MD, IDEAYA Biosciences
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Erkrankungen des endokrinen Systems
- Pathologische Prozesse
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Neubildungen
- Männliche Urogenitalerkrankungen
- Urologische Erkrankungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Krankheitsattribute
- Erkrankungen der Atemwege
- Neubildungen nach histologischem Typ
- Gastrointestinale Neubildungen
- Neoplasmen des Verdauungssystems
- Erkrankungen des Verdauungssystems
- Magen-Darm-Erkrankungen
- Lungenkrankheit
- Neoplasmen der endokrinen Drüse
- Kopf-Hals-Neubildungen
- Erkrankungen der Bauchspeicheldrüse
- Neubildungen, Drüsen und Epithelien
- Neubildungen der Atemwege
- Thoraxneoplasmen
- Neoplastische Prozesse
- Erkrankungen der Speiseröhre
- Lungentumoren
- Adenom
- Neubildungen, Mesothel
- Pleuraneoplasmen
- Urologische Neubildungen
- Karzinom
- Neubildungen, Plattenepithelzellen
- Erkrankungen der Harnblase
- Karzinom, Plattenepithel
- Ösophagusneoplasmen
- Pathologische Zustände, Anzeichen und Symptome
- Plattenepithelkarzinom des Ösophagus
- Mesotheliom, bösartig
- Wiederauftreten
- Mesotheliom
- Neoplasma Metastasierung
- Neoplasmen der Bauchspeicheldrüse
- Neoplasien der Harnblase
- Karzinom, Übergangszelle
- Adenokarzinom der Speiseröhre
Andere Studien-ID-Nummern
- IDE892-001
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .